Program Overview

Cardiovascular disease continues to dominate our society and remains the number #1 killer worldwide in both men and women. Approximately one-third of total deaths globally are a result of the various forms of cardiovascular disease. A cardiovascular disease-related event causes a death every minute in the United States; therefore, the field of Cardiovascular Disease in terms of diagnosis and treatment continues to evolve with the final goal of improving the overall care and prognosis of patients suffering from a variety of cardiovascular diseases.

The Top Ten Topics in Clinical Cardiology is poised to help healthcare professionals stay current on new and emerging approaches in the diagnosis, management and treatment of heart disease, including COVID-19. A robust agenda combines individual and collective opinions from field expert clinicians and scholars. This year, the COVID-19 pandemic has taken the center stage in various cardiovascular and respiratory disease processes.

Program Goal

As a comprehensive virtual medical education conference, this course will offer the latest updates for diagnostic and treatment strategies that assess the risk and treatment of coronary artery disease, congestive heart failure, hypertension, LA appendage closure, mitral valve regurgitation, aortic stenosis, and co-morbid cardiometabolic diseases and the COVID-19 infection. The use of case-based reviews and taped case presentations will demonstrate innovative therapeutic techniques aimed at improving patient outcomes and quality of life, as well as lowering morbidity and mortality rates through the management of various conditions.

Target Audience

General Cardiologists, Interventional Cardiologists, Internists, Family Practitioners, Cardiology Fellows, Nurses, Technicians and other allied health care professionals.


The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for physicians.

Credit Designation

The Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credit(s).TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Verification of Attendance

Verification of attendance will be provided to all professionals.

Learning Objectives

Looking into the future of what cardiovascular medicine will become over the next few years, the overall goal of this program is to enhance competency by providing participants with the most up-to-date developments in the diagnosis, treatment and management of cardiovascular disease and to facilitate this transfer of knowledge into practice to improve patient outcomes.

Upon completion of this program, attendees should be able to:

  • Comprehend the COVID-19 disease process and outcomes.
  • Learn to assess various CAD risk factors and imaging to provide diagnostic and prognostic information and appropriate treatment.
  • Acknowledge, through evidence-based results, recent transcatheter valve therapies with special focus on mitral and triscupid valve procedures.
  • Recognize the issues pertaining to various antithrombotics post DES.
  • Incorporate the latest advances within interventional cardiology and their implications in overall patient care, improving interventional outcomes.

Conference Information

For additional information, email

Registration Fees

This course will be complimentary, but if you would like your CME certificate that will
come at a cost of $25.

Faculty Disclosure

It is the policy of ISMMS to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.